Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has shared an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announces an estimated substantial increase in net profit for FY2024, ranging from approximately RMB2,150 million to RMB2,390 million, indicating a year-on-year rise of 118% to 142%. However, when adjusted for non-recurring gains or losses, the net profit is expected to show a decrease, suggesting a complex financial outlook for stakeholders.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, operates in the pharmaceutical industry. It is incorporated in the People’s Republic of China and focuses on producing and distributing pharmaceutical products and services.
YTD Price Performance: 1.21%
Average Trading Volume: 33
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €3.46B
For detailed information about 2TZ stock, go to TipRanks’ Stock Analysis page.
